

Table 1. Demographic characteristics between THZ and comparison cohort in CKD population.

	Before matching (n=24,312)				P value	After matching (n=17,002)				P value
	THZ cohort (n=9784)		Comparison cohort (n=14,528)			THZ cohort (n=8501)		Comparison cohort (n=8501)		
Age(Mean±SD)	64.67	(±12.43)	59.74	(±16.03)	<0.001	64.11	(±12.67)	64.30	(±13.24)	0.340
20-44	970	(6.8)	2786	(19.2)		656	(7.7)	575	(6.8)	
45-64	3911	(40.0)	5731	(39.4)		3506	(41.2)	3491	(41.1)	
65-74	3008	(30.7)	3217	(22.1)		2497	(29.4)	2533	(29.8)	
75-100	2195	(22.4)	2794	(19.2)		1842	(21.7)	1902	(22.4)	
Gender (%)										
Female	5294	(54.1)	7036	(48.4)	<0.001	4456	(52.4)	4350	(51.2)	0.104
Male	4490	(45.9)	7492	(51.6)		4045	(47.6)	4151	(48.8)	
Region										
Northern	4094	(41.8)	6588	(45.3)	<0.001	3674	(43.2)	3750	(44.1)	0.563
Central	2886	(29.5)	3869	(26.6)		2427	(28.5)	2338	(27.5)	
Southern and eastern	2804	(28.7)	4071	(28.0)		2400	(28.2)	2413	(28.4)	
Visit nephrologist within 3 year before index date										
0	7674	(78.4)	11745	(80.8)	<0.001	6727	(79.1)	6651	(78.2)	0.133
1-6	1560	(15.9)	2030	(14.0)		1293	(15.2)	1335	(15.7)	
>6	550	(5.6)	753	(5.2)		481	(5.7)	515	(6.1)	
Comorbidities(%)										
Diabetes	4399	(45.0)	4834	(33.3)	<0.001	3636	(42.8)	3706	(43.6)	0.278
Coronary artery disease	634	(6.5)	843	(5.8)	0.196	526	(6.3)	604	(7.1)	0.051
Congestive heart failure	441	(4.5)	598	(4.1)	0.567	377	(4.4)	401	(4.7)	0.378
Acute myocardial fraction	295	(3.0)	493	(3.4)	0.025	270	(3.2)	298	(3.5)	0.232
Peripheral vascular disease	147	(1.5)	234	(1.6)	0.372	129	(1.5)	135	(1.6)	0.710
Peripheral vascular disease	147	(1.5)	234	(1.6)	0.372	129	(1.5)	135	(1.6)	0.710

Table 1. Demographic characteristics between THZ and comparison cohort in CKD population. (Cont'd)

	Before matching (n=24,312)				P value	After matching (n=17,002)				P value
	THZ cohort (n=9784)		Comparison cohort (n=14528)			THZ cohort (n=8501)		Comparison cohort (n=8501)		
Cerebral vascular disease	342	(3.5)	528	(3.6)	0.251	313	(3.7)	331	(3.9)	0.495
Cancer	140	(1.4)	289	(2.0)	<0.001	130	(1.5)	119	(1.4)	0.483
Charlson comorbidity index										
0	8023	(82.0)	11814	(81.3)	0.007	6940	(81.6)	6862	(80.7)	0.219
1	1353	(13.8)	2182	(15.0)		1224	(14.4)	1265	(14.9)	
≥2	408	(4.2)	532	(3.7)		337	(4.0)	374	(4.4)	
Medication										
ACEI	3480	(35.6)	3027	(20.8)	<0.001	2684	(31.6)	2686	(31.6)	0.974
ARB	2551	(26.1)	2222	(15.3)	<0.001	1966	(23.1)	1965	(23.1)	0.985
α-Blockers	1362	(13.9)	1498	(10.3)	<0.001	1081	(12.7)	1105	(13.0)	0.582
β-Blockers	4358	(44.5)	4331	(29.8)	<0.001	3483	(41.0)	3485	(41.0)	0.975
Calcium channel blockers										
Nondihydropyridine	1145	(11.7)	1064	(7.3)	<0.001	883	(10.4)	891	(10.5)	0.841
Dihydropyridine	5002	(51.1)	4493	(30.9)	<0.001	3929	(46.2)	4006	(47.1)	0.237
Other antihypertensives	721	(7.4)	292	(2.0)	<0.001	287	(3.4)	335	(3.9)	0.051
Loop diuretics	982	(10.0)	1307	(8.9)	<0.001	803	(9.4)	765	(8.9)	0.063
THZ-type and THZ-like										
THZ-type	4301	(44.0)				3747	(44.1)			
Metolazone	491	(5.0)				419	(4.9)			
Chlorthalidone	219	(2.2)				189	(2.2)			
Indapamide	4773	(48.8)				4146	(48.8)			

Abbreviation: SD=standard deviation.

The difference of two cohort was estimated by independent t test or chi-square test.

*THZ: bendrofulmethiazide, and hydrochlorothiazide